secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108859
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026
--------------------------------------------------------------------------------

- Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.
- Cash and equivalents $227.0M as of June 30, 2025; runway into Q4 2026.
- Tanruprubart MAA for GBS submission expected Q1 2026; FDA BLA discussions ongoing.
- Vonaprument ARCHER II Phase 3 enrollment completed (659 patients); topline data H2 2026.
- ANX1502 oral C1s inhibitor POC trial update in CAD anticipated by year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017025108859/0000950170-25-108859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017025108859/annx-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer